Literature DB >> 29663170

Racial/ethnic disparities and incidence of malignant peripheral nerve sheath tumors: results from the Surveillance, Epidemiology, and End Results Program, 2000-2014.

Erin C Peckham-Gregory1,2, Roberto E Montenegro3, David A Stevenson4, David H Viskochil5, Michael E Scheurer1,2, Philip J Lupo1,2, Joshua D Schiffman6.   

Abstract

BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are rare tumors, generally high-grade, and comprise ~ 5-10% of soft tissue sarcomas. Over two-thirds of MPNSTs metastasize, and upwards of 40% clinically recur. Etiologic risk factors for MPNSTs are historically understudied. There is evidence to suggest MPNST incidence differs across racial/ethnic groups in pediatric populations. Therefore, we sought to estimate differences in MPNST incidence by race/ethnicity among all ages in the United States.
METHODS: Incidence data were obtained from the Surveillance, Epidemiology, and End Results (SEER-18) Program, 2000-2014. Race/ethnicity was categorized as: White; Black; Asian; Other; and Latino/a ("Spanish-Hispanic-Latino"). Latino/a included all races, while all other categories excluded those identified as Latino/a. Age-adjusted incidence rate ratios (IRR) and 95% confidence intervals (CIs) were generated in SEER-STAT (v8.3.4). We estimated incidence rates among all ages, and among those diagnosed < 25 and ≥ 25 years.
RESULTS: MPNST cases were abstracted from SEER-18 (n = 1047). Among all age groups, Blacks experienced an elevated incidence of MPNSTs compared to Whites (IRRBlacks = 1.26, 95% CI 1.04-1.50). Asian and Latinos/as experienced lower incidences compared to Whites (IRRAsians = 0.78, 95% CI 0.61-0.99; IRRLatinos/as = 0.84, 95% CI 0.69-1.02). In subgroup analyses, no statistically significant associations with MPNSTs were identified among cases diagnosed < 25 years of age, whereas the associations observed among all age groups were prominent among those diagnosed ≥ 25 years of age.
CONCLUSIONS: Incidence rates of MPNSTs were highest in Blacks compared to Whites and other minority groups. This study suggests specific patterns exist in terms of race/ethnicity and age at diagnosis of MPNSTs.

Entities:  

Keywords:  Epidemiology; Malignant peripheral nerve sheath tumors; Race/ethnicity; SEER

Mesh:

Year:  2018        PMID: 29663170     DOI: 10.1007/s11060-018-2842-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  20 in total

1.  Racial differences in vestibular schwannoma.

Authors:  Matthew L Carlson; Alexander P Marston; Amy E Glasgow; Elizabeth B Habermann; Alex D Sweeney; Michael J Link; George B Wanna
Journal:  Laryngoscope       Date:  2016-02-24       Impact factor: 3.325

2.  Malignant peripheral nerve sheath tumors in neurofibromatosis 1.

Authors:  A A King; M R Debaun; V M Riccardi; D H Gutmann
Journal:  Am J Med Genet       Date:  2000-08-28

3.  Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.

Authors:  Q Fan; J Yang; G Wang
Journal:  Clin Transl Oncol       Date:  2013-06-08       Impact factor: 3.405

4.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

Review 5.  Malignant peripheral nerve sheath tumors.

Authors:  Mohamad Farid; Elizabeth G Demicco; Roberto Garcia; Linda Ahn; Pamela R Merola; Angela Cioffi; Robert G Maki
Journal:  Oncologist       Date:  2014-01-27

6.  Nativity disparities in late-stage diagnosis and cause-specific survival among Hispanic women with invasive cervical cancer: an analysis of Surveillance, Epidemiology, and End Results data.

Authors:  Jane R Montealegre; Renke Zhou; E Susan Amirian; Michele Follen; Michael E Scheurer
Journal:  Cancer Causes Control       Date:  2013-08-11       Impact factor: 2.506

7.  Malignant peripheral nerve sheath tumors of the head and neck: Demographics, clinicopathologic features, management, and treatment outcomes.

Authors:  Armin Arshi; Bobby A Tajudeen; Maie St John
Journal:  Oral Oncol       Date:  2015-10-09       Impact factor: 5.337

8.  Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1.

Authors:  Roberto André Torres de Vasconcelos; Pedro Guimarães Coscarelli; Regina Papais Alvarenga; Marcus André Acioly
Journal:  Arq Neuropsiquiatr       Date:  2017-06       Impact factor: 1.420

Review 9.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

10.  Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1.

Authors:  In Kyung Hwang; Seung Min Hahn; Hyo Sun Kim; Sang Kyum Kim; Hyo Song Kim; Kyoo-Ho Shin; Chang Ok Suh; Chuhl Joo Lyu; Jung Woo Han
Journal:  Cancer Res Treat       Date:  2016-12-01       Impact factor: 4.679

View more
  1 in total

1.  Incidence of second malignancies in individuals diagnosed with malignant peripheral nerve sheath tumors.

Authors:  Lindsay A Williams; Christopher L Moertel; Michaela Richardson; Erin L Marcotte
Journal:  J Neurooncol       Date:  2020-04-01       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.